Invivyd, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Invivyd, Inc. (IVVD) on September 22, 2025. The filing addresses corporate governance changes and regulatory compliance status regarding the company's listing on The Nasdaq Stock Market.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The only financial data disclosed relates to director compensation:
- Director Cash Retainer: $40,000 annually for Board service.
- Committee Retainer: $5,000 annually for Compensation Committee service.
- Equity Grant: Nonqualified option to acquire 100,000 shares of common stock, vesting over three years.
Material Changes
Board Composition:
- Appointment: Paul B. Bolno, M.D., was appointed as a director and to the Compensation Committee, effective September 22, 2025.
- Resignation: Christine Akinc resigned from the Board and all committees effective September 22, 2025. The resignation was not due to any disagreement with the Company.
Listing Status:
- The Company regained compliance with Nasdaq Listing Rule 5450(a)(1) (Minimum Bid Price Requirement) as of September 22, 2025.
- Previously, on April 21, 2025, the Company was notified of non-compliance due to the stock closing below $1.00 per share for 30 consecutive business days.
- Compliance was achieved by maintaining a closing bid price of at least $1.00 per share for ten consecutive business days.
Outlook, Risks, and Contingencies
Indemnification: The Company entered into a standard indemnification agreement with Dr. Bolno, which may require the Company to indemnify him for expenses, judgments, fines, and settlement amounts incurred in actions arising from his service as a director.
Regulatory Status: The matter regarding the Minimum Bid Price Requirement is now closed, removing the immediate risk of delisting associated with this specific rule.
Investor Verification Checklist
- Verify the current stock price to ensure continued compliance with the $1.00 minimum bid price requirement.
- Review the full terms of the 2021 Equity Incentive Plan regarding the 100,000 share option granted to Dr. Bolno.
- Confirm the composition of the Board and Compensation Committee following the transition.
- Check for any subsequent press releases or filings regarding the Company's financial performance, as this 8-K contains no operational financial data.